PT - JOURNAL ARTICLE AU - Dulovic, Alex AU - Strengert, Monika AU - Ramos, Gema Morillas AU - Becker, Matthias AU - Griesbaum, Johanna AU - Junker, Daniel AU - Lürken, Karsten AU - Beigel, Andrea AU - Wrenger, Eike AU - Lonnemann, Gerhard AU - Cossmann, Anne AU - Stankov, Metodi V. AU - Dopfer-Jablonka, Alexandra AU - Kaiser, Philipp D. AU - Traenkle, Bjoern AU - Rothbauer, Ulrich AU - Krause, Gérard AU - Schneiderhan-Marra, Nicole AU - Behrens, Georg M.N. TI - Diminishing immune responses against variants of concern in dialysis patients four months after SARS-CoV-2 mRNA vaccination AID - 10.1101/2021.08.16.21262115 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.16.21262115 4099 - http://medrxiv.org/content/early/2021/08/20/2021.08.16.21262115.short 4100 - http://medrxiv.org/content/early/2021/08/20/2021.08.16.21262115.full AB - Patients undergoing chronic hemodialysis were among the first to receive SARS-CoV-2 vaccinations due to their increased risk for severe COVID-19 disease and high case fatality rates. To date, there have been minimal longitudinal studies in hemodialysis patients to ascertain whether protection offered by vaccination is long-lasting. To assess how surrogates for protection changed over time, we examined both the humoral and cellular response in a previously reported cohort of at-risk hemodialysis patients and healthy donors, four months after their second dose of Pfizer BNT162b2. Compared to three weeks post-second vaccination, both cellular and humoral responses against the original SARS-CoV-2 isolate as well as variants of concern were significantly reduced, with some dialyzed individuals having no B- or T-cell response. Our data strongly support the need for a third booster in hemodialysis patients and potentially other at-risk individuals.Competing Interest StatementNSM was a speaker at Luminex user meetings in the past. The Natural and Medical Sciences Institute at the University of Tuebingen is involved in applied research projects as a fee for services with the Luminex Corporation. The other authors declare no competing interestFunding StatementThis work was funded by the Initiative and Networking Fund of the Helmholtz Association of German Research Centers, EU Horizon 2020 research and innovation program and the State Ministry of Baden-Wuerttemberg for Economic Affairs, Labour and Tourism.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Internal Review Board of Hannover Medical School (MHH, approval number 8973_BO-K_2020, amendment Dec. 2020). Written informed consent was obtained from all participants prior to study start.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available from the corresponding authors upon request.